Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

20.12.24	U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer (Businesswire)
19.12.24	Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts (Businesswire)
17.12.24	Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance (Businesswire)
12.12.24	Pfizer Declares First-Quarter 2025 Dividend (Businesswire)
10.12.24	Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance (Businesswire)
05.12.24	Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS (Businesswire)
20.11.24	Pfizer Announces New Chief Scientific Officer and President, Research & Development (Businesswire)
20.11.24	European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors (Businesswire)
14.11.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
04.11.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
29.10.24	Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance (Businesswire)
23.10.24	Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older (Businesswire)
22.10.24	U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease (Businesswire)
15.10.24	Tim Buckley Elected to Pfizer’s Board of Directors (Businesswire)
11.10.24	U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors (Businesswire)
10.10.24	Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial (Businesswire)
09.10.24	Pfizer Declares Fourth-Quarter 2024 Dividend (Businesswire)
08.10.24	Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024 (Businesswire)
25.09.24	Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets (Businesswire)
20.09.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union (Businesswire)
17.09.24	Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts (Businesswire)
14.09.24	Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia (Businesswire)
14.09.24	Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer (Businesswire)
11.09.24	Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024 (Businesswire)
28.08.24	Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
27.08.24	Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare (Businesswire)
22.08.24	Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine (Businesswire)
16.08.24	Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age (Businesswire)
12.08.24	Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults (Businesswire)
30.07.24	Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance (Businesswire)
25.07.24	European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.07.24	Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate (Businesswire)
11.07.24	Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron (Businesswire)
09.07.24	Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development (Businesswire)
01.07.24	Cyrus Taraporevala Elected to Pfizer’s Board of Directors (Businesswire)
27.06.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union (Businesswire)
26.06.24	Pfizer Declares Third-Quarter 2024 Dividend (Businesswire)
18.06.24	Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts (Businesswire)
14.06.24	ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma (Businesswire)
12.06.24	Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy (Businesswire)
03.06.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.24	Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Businesswire)
31.05.24	Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression (Businesswire)
06.05.24	Pfizer Announces New Chief Strategy and Innovation Officer (Businesswire)
01.05.24	Pfizer Reports First-Quarter 2024 Results (Businesswire)
30.04.24	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer (Businesswire)
29.04.24	Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting (Businesswire)
26.04.24	U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.04.24	Pfizer Declares Second-Quarter 2024 Dividend (Businesswire)
22.04.24	European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Swiss Re	130.20	1.32 %	K V
Roche Hldg G	250.60	1.29 %	K V
Holcim	87.16	1.23 %	K V
Novartis	87.75	1.19 %	K V
Zurich Insur Gr	539.20	1.16 %	K V
Sonova Hldg	296.50	0.30 %	K V
Part Grp Hldg	1’213.50	0.21 %	K V
Sika	213.50	0.14 %	K V
Nestle	73.94	-0.05 %	K V
Geberit	512.00	-0.43 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Pfizer Inc Cert.Deposito Arg.Repr. 0.5 Shs

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten